Physician profile
Ken E Parschauer
NPI 1225097884
$1,444.95
in general payments reported to CMS, 2019-2025
14 companies · $39.43 in 2025
The $39.43 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $247 · 2021: $372 · 2022: $315 · 2023: $157 · 2024: $95.92 · 2025: $39.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $351.50 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $239.46 | 2020-2021 | |
| Alcon Vision LLC | $227.30 | 2019-2024 | Hydrus Microstent, Clareon |
| Allergan, INC. | $190.21 | 2019-2021 | |
| New World Medical,INC. | $136.74 | 2022 | |
| Abbvie INC. | $101.92 | 2022-2025 | |
| Rayner Intraocular Lenses Limited | $35.46 | 2022-2024 | Rayone Spheric, Omidria, Rayone Emv |
| Horizon Therapeutics Plc | $33.77 | 2023 | Tepezza |
| Dompe US, INC. | $31.36 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $28.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.54 | 2022 | |
| Amgen INC. | $17.88 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $15.21 | 2022 | |
| Glaxosmithkline, LLC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Parschauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.